Clinical Trial Search

Primary: Part I Only: Clinical Benefit Rate (CR+PR+SD≥6months) of Patients Who Received Neratinib Alone — 5 Participants

Primary: Cardiac Saftey — 68; 67; 66; 65 percentage of LVEF

Primary: Objective Response Rate Per Composite Response Criteria — 7.5; 48.6; 33.3 percent of participants

Primary: Percentage of Patients With HER2- Primary Breast Cancer Who Develop Imagable HER2+ Metastases — 13 % of participants

Primary: Pathologic Complete Response Rate (PCRR), the Percentage of Patients Who Have No Evidence of Cancer in the Breast or Lymph Nodes Following Surgery — 56 percentage of…

Primary: Overall Response Rate (ORR) — 30 percentage of participants

Primary: Treatment-emergent Adverse Events Following Treatment With DS-8201a (Trastuzumab Deruxtecan) — 12; 12; 7; 6 Participants

Primary: Clinical Response — 3; 30; 11; 3 participants

Primary: Number of Participants With a Best Overall Response (OR) of Confirmed Complete Response (CR) or Partial Response (PR), as Assessed by the Independent Review Committee…

Primary: Dose-Limiting Toxicity (DLT) of MK-3475 in Combination With Trastuzumab — 0; 0 Participants

Primary: Progression-Free Survival (PFS) of MTD/Phase II Patients — 4.0 months

Primary: Number of Patients Who Completed All Planned Therapy — 45 participants

Primary: Objective Response for HER2+ Patients (Best Objective Response a Patient Has Ever Experienced on Study) — 3; 13; 10; 11 Participants

Primary: Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs) — 3; 3; 15; 15 Participants

Primary: 16-week Progression Free Survival — 58.2; 77.8 percentage of participants

Primary: Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer…

Primary: 16 Weeks PFS Per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) (Cohort 1) — 1; 7 Participants

Primary: The Objective Response Rate as Defined as Stable Disease or the Rate of Complete and Partial Responses Determined on Two Consecutive Occasions Greater Than or Equal to 4…

Primary: Incidence of Treatment-emergent AE's — 16 participants

Primary: Optimal Dose of RAD001 in Combination With Trastuzumab (Phase I) — 10 mg

Primary: Objective Response Rate (ORR) (Phase II) — 0; 5; 14 Participants

Primary: Progression-free Survival(PFS) — 4.7; 3.7 Months — p=0.44

Primary: Progression Free Survival (PFS) at the Time of Primary Results — 8.97; 11.30; 9.13; 13.63 Months — p=0.0010

Primary: Overall Tumor Response — 1; 8; 18; 29 participants

Primary: Percentage of Patients Who Complete Planned Oncologic Therapy Without the Development of a Cardiac Event or Asymptomatic Worsening of Cardiac Function. — 27 Participants

Primary: Pathologic Complete Response in Breast and Axillary Lymph Nodes. — 16; 14; 21; 5 Participants

Primary: Part I: Progression Free Survival (PFS) by Biomarker — NA; NA; 13.963; 1.216 months

Primary: Estimate Efficacy of Capecitabine 7/7 in Combination With Lapatinib in Patients With HER2 Overexpressed/Amplified, Trastuzumab-refractory, Metastatic Breast Cancer as…

Primary: Number of Participants With Tumor Response (Stable Disease) — 5 participants

Primary: Estimate Progression-free Survival — 16.9; 8.3 Months